Debut Launches PNar, a New Dark-Spot Ingredient for Skincare Brands

September 15, 2026 · 12:56 p.m. ET

By Regina Bonham Bordeaux

Debut has launched PNar™, a new skincare ingredient developed for dark spots and uneven tone. You cannot buy PNar as a standalone skincare product; Debut is offering it to U.S. skincare brands for future formulas.^[1]

Debut says early testing looks promising, but the public information still leaves important questions unanswered. For now, PNar is worth watching rather than replacing a well-established brightening ingredient.

What launched

PNar is designed to reduce excess pigment by blocking enzymes involved in melanin production, including tyrosinase. Debut positions it as an alternative to familiar dark-spot ingredients such as kojic acid.^[1]

Debut’s ingredient pipeline lists PNar as launched for hyperpigmentation. The company reports a 20.6% improvement in skin radiance after 12 weeks of twice-daily use compared with baseline.^[2]

Why it matters

Dark-spot products often compete on ingredient percentages, but percentages from different ingredients are not directly comparable. Debut says PNar is designed for use at 0.45%. The European Union limits kojic acid to 1% in face and hand products when it is used for skin lightening.^[3]

That does not mean PNar is automatically stronger, gentler or more effective because its percentage is lower. What matters is how much improvement you actually see once PNar is used in a finished serum, cream or treatment—and how well those products are tolerated.

To see how PNar’s early claims compare with the human evidence for Thiamidol, hydroquinone, Melasyl, and other approaches, read BB’s Which Dark-Spot Ingredients Actually Work?. Different pigmentation mechanisms are not automatically better-performing products.

What we know

Debut reports that 97% of users in a 12-week clinical study showed improvement in hyperpigmentation and 88% showed improvement in skin brightening.^[1]

Those numbers sound encouraging, but the announcement does not say how many people were studied, what PNar was compared with, which skin tones were included, how improvement was graded or how large the average improvement was. Without those details, you cannot tell how PNar compares with established options.

For context, BB’s Thiamidol IngredientBrief examines controlled human pigmentation studies, while the Hydroquinone IngredientBrief explains the evidence and prescription-only U.S. treatment context for melasma. Those are different evidence and regulatory situations, not head-to-head comparisons proving that PNar is better or worse.

Debut also says PNar brightens without the irritation associated with some older pigment ingredients. The public announcement does not provide comparative irritation results, so that claim cannot yet be independently assessed.^[1]

There is another practical unknown: Debut has not publicly identified PNar’s INCI name, the standardized ingredient name shoppers would expect to see on a product label. Until that is disclosed, it is not yet clear how you will identify PNar when it starts appearing in finished products.

What we’re watching

The next useful information will be fuller clinical-study details, PNar’s ingredient-list name and the first U.S. products formulated with it.

That is when you will be able to judge the question that matters most: whether PNar-containing products noticeably improve dark spots without creating enough irritation to make consistent use difficult.